PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization
PAVmed Inc. (PAVM)
US:NASDAQ Investor Relations:
ir.pavm.com
Company Research
Source: GlobeNewswire
Extends cash runway to support multiple milestones including commercialization of two lead products NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has entered into a financing agreement (the “Financing”) with an existing and a new institutional investor for a maximum amount of $14 million. Proceeds from the Financing will be used to support continued advancement of PAVmed’s lead products to commercialization and for general working capital purposes. Maxim Group LLC acted as financial advisor in this transaction. Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, commented, “We are pleased to secure this Financing, which significantly enhances our financial flexibility by providing immediate near-term capital and access to a committed second tranche at our discretion. Importantly, it enables PAVmed to execute on the clinical an
Show less
Read more
Impact Snapshot
Event Time:
PAVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PAVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PAVM alerts
High impacting PAVmed Inc. news events
Weekly update
A roundup of the hottest topics
PAVM
News
- Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test [Yahoo! Finance]Yahoo! Finance
- Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]Yahoo! Finance
- PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring [Yahoo! Finance]Yahoo! Finance
- PAVmed Inc. 2024 Q3 - Results - Earnings Call Presentation [Seeking Alpha]Seeking Alpha
- PAVmed Provides Business Update and Third Quarter 2024 Financial ResultsPR Newswire
PAVM
Earnings
- 11/14/24 - Beat
PAVM
Analyst Actions
- 9/10/24 - Ascendiant Capital
PAVM
Sec Filings
- 11/21/24 - Form PRE
- 11/21/24 - Form 8-K
- 11/14/24 - Form SC
- PAVM's page on the SEC website